eTumorType, An Algorithm of Discriminating Cancer Types for Circulating Tumor Cells or Cell-free DNAs in Blood

Genomics, Proteomics and Bioinformatics

Volumn 15, Issue 2, 2017, Pages 130-140

  Zou, Jinfeng ^a   Wang, Edwin ^{a,b,c,d,e,f,g}  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e ALBERTA CHILDREN S HOSPITAL RESEARCH INSTITUTE   (Canada)

^f Division of Endocrinology   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cancer; Copy number variation; eTumorType; Founding clone; Non invasive detection

Indexed keywords

CELL FREE DNA; DNA; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BRAIN CANCER; BREAST CANCER; CELL FREE SYSTEM; CIRCULATING TUMOR CELL; CLONE; COLON CANCER; COPY NUMBER VARIATION; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CANCER; ETUMORTYPE; GENE ONTOLOGY; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASM; MARKOV CHAIN; NON INVASIVE MEASUREMENT; OVARY CANCER; PREDICTIVE VALUE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; STOMACH CANCER; BLOOD; CELL CLONE; FEMALE; GENETICS; GENOMICS; MALE; METABOLISM; NEOPLASMS; ONCOLOGY; PROCEDURES; TUMOR EMBOLISM;

ALGORITHMS; CLONE CELLS; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; GENOMICS; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 85017470163     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2017.01.004     Document Type: Article

References (40)

1. [1] Murtaza, M., Dawson, S.J., Tsui, D.W., Gale, D., Forshew, T., Piskorz, A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 (2013), 108–112.
2. [2] Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E.M., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73 (2013), 2965–2975.
3. [3] Vallee, A., Marcq, M., Bizieux, A., Kouri, C.E., Lacroix, H., Bennouna, J., et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 82 (2013), 373–374.
4. [4] Hou, H.W., Warkiani, M.E., Khoo, B.L., Li, Z.R., Soo, R.A., Tan, D.S., et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep, 3, 2013, 1259.
5. [5] Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7 (2012), 115–121.
6. [6] Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014;2:107.
7. [7] Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013;5:207ps14.
8. [8] Miller, C.A., White, B.S., Dees, N.D., Griffith, M., Welch, J.S., Griffith, O.L., et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol, 10, 2014, e1003665.
9. [9] Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., et al. The life history of 21 breast cancers. Cell 149 (2012), 994–1007.
10. [10] Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30 (2012), 413–421.
11. [11] Lockwood, W.W., Chari, R., Coe, B.P., Girard, L., Macaulay, C., Lam, S., et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 27 (2008), 4615–4624.
12. [12] Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 45 (2013), 1134–1140.
13. [13] Gao, S., Tibiche, C., Zou, J., Zaman, N., Trifiro, M., O'Connor-McCourt, M., et al. Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer. JAMA Oncol 2 (2016), 37–45.
14. [14] Li, J., Lenferink, A.E., Deng, Y., Collins, C., Cui, Q., Purisima, E.O., et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun, 1, 2010, 34.
15. [15] Breiman, L., Random forests. Mach Learn 45 (2001), 5–32.
16. [16] Culp, M., Johnson, K., Michailidis, G., Ada: an R package for stochastic boosting. Gen Inf 17 (2006), 1–27.
17. [17] Mermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhim, R., Getz, G., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol, 12, 2011, R41.
18. [18] Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., Mesirov, J.P., GenePattern 2.0. Nat Genet 38 (2006), 500–501.
19. [19] Zaman, N., Li, L., Jaramillo, M.L., Sun, Z., Tibiche, C., Banville, M., et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. Cell Rep 5 (2013), 216–223.
20. [20] The Gene Ontology Consortium, Gene Ontology Consortium: going forward. Nucleic Acids Res 43 (2015), D1049–D1056.
21. [21] Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25 (2000), 25–29.
22. [22] Binns, D., Dimmer, E., Huntley, R., Barrell, D., O'Donovan, C., Apweiler, R., QuickGO: a web-based tool for Gene Ontology searching. Bioinformatics 25 (2009), 3045–3046.
23. [23] Wang, E., Zaman, N., McGee, S., Milanese, J.S., Masoudi-Nejad, A., O'Connor-McCourt, M., Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol 30 (2015), 4–12.
24. [24] Wang, E., Understanding genomic alterations in cancer genomes using an integrative network approach. Cancer Lett 340 (2013), 261–269.
25. [25] Chicard, M., Boyault, S., Colmet Daage, L., Richer, W., Gentien, D., Pierron, G., et al. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin Cancer Res 22 (2016), 5564–5573.
26. [26] de Las Casas, C.M., Gonzalez-Cao, M., Ramirez, S.V., Ariza, N.J., Balada, A., Garzon, M., et al. Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. Transl Lung Cancer Res 5 (2016), 532–537.
27. + circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer. Oncotarget 7 (2016), 77389–77403.
28. [28] Meng, X., Muller, V., Milde-Langosch, K., Trillsch, F., Pantel, K., Schwarzenbach, H., Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget 7 (2016), 16923–16935.
29. [29] Skrypkina, I., Tsyba, L., Onyshchenko, K., Morderer, D., Kashparova, O., Nikolaienko, O., et al. Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer. Dis Markers, 2016, 2016, 3693096.
30. [30] Yan, W., Zhang, A., Powell, M.J., Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors. Chin J Cancer, 35, 2016, 68.
31. [31] Wang, E., Zou, J., Zaman, N., Beitel, L.K., Trifiro, M., Paliouras, M., Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. Semin Cancer Biol 23 (2013), 286–292.
32. [32] Wang, E., Zou, J., Zaman, N., Beitel, L.K., Trifiro, M., Paliouras, M., Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. Semin Cancer Biol 23 (2013), 279–285.
33. [33] Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L.M., Roth, A., et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 231 (2013), 21–34.
34. [34] Leiserson, M.D., Vandin, F., Wu, H.T., Dobson, J.R., Eldridge, J.V., Thomas, J.L., et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet 47 (2015), 106–114.
35. [35] Kirkizlar, E., Zimmermann, B., Constantin, T., Swenerton, R., Hoang, B., Wayham, N., et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol 8 (2015), 407–416.
36. [36] Mathiesen, R.R., Fjelldal, R., Liestol, K., Due, E.U., Geigl, J.B., Riethdorf, S., et al. High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer 131 (2012), E405–E415.
37. [37] Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6, 2014, 22ra24.
38. [38] Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20 (2014), 548–554.
39. [39] Lohr, J.G., Adalsteinsson, V.A., Cibulskis, K., Choudhury, A.D., Rosenberg, M., Cruz-Gordillo, P., et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32 (2014), 479–484.
40. [40] Onstenk, W., Sieuwerts, A.M., Weekhout, M., Mostert, B., Reijm, E.A., van Deurzen, C.H., et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Lett 362 (2015), 36–44.